The value of F-18-fluorodeoxyglucose pet for the 3-D radiation treatment planning of malignant gliomas

International Journal of Radiation Oncology Biology Physics

Volumn 41, Issue 5, 1998, Pages 989-995

  Gross, Markus W ^a   Weber, Wolfgang A ^a   Feldmann, Horst Jürgen ^a   Bartenstein, Peter ^a   Schwaiger, Markus ^a   Molls, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

3D treatment planning; F 18 Fluorodeoxyglucose; Malignant glioma; MRI; PET; Radiotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN TISSUE; CONTRAST ENHANCEMENT; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; TREATMENT PLANNING; TUMOR VOLUME; WHITE MATTER;

ADULT; AGED; ASTROCYTOMA; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; GADOLINIUM DTPA; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; SUPRATENTORIAL NEOPLASMS; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032527662     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00183-7     Document Type: Article

References (25)

1. Fine H.A., Dear K.B., Loeffler J.S., Black P.M., Canellos G.P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 71:1993;2585-2597.
2. Salcman, M.; Scholtz, H.; Kaplan, R. S.; Kulik, S. Long-term survival in patients with malignant astrocytoma. Neurosurgery 34:213-219; discussion 219-220; 1994.
3. Thornton A.F. Jr, Sandler H.M., Ten Haken R.K., McShan D.L., Fraass B.A., La Vigne M.L., Yanke B.R. The clinical utility of magnetic resonance imaging in 3-dimensional treatment planning of brain neoplasms. Int. J. Radiat. Oncol. Biol. Phys. 24:1992;767-775.
4. Paulus W., Peiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer. 64:1989;442-447.
5. Alavi J.B., Alavi A., Chawluk J., Kushner M., Powe J., Hickey W., Reivich M. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer. 62:1988;1074-1078.
6. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest. Radiol. 22:1987;360-371.
7. Di Chiro G., DeLaPaz R.L., Brooks R.A., Sokoloff L., Kornblith P.L., Smith B.H., Patronas N.J., Kufta C.V., Kessler R.M., Johnston G.S., Manning R.G., Wolf A.P. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 32:1982;1323-1329.
8. Lammertsma A.A. Positron emission tomography and in vivo measurements of tumour perfusion and oxygen utilisation. Cancer Metastasis Rev. 6:1987;521-539.
9. Olivero W.C., Dulebohn S.C., Lister J.R. The use of PET in evaluating patients with primary brain tumours is it useful? J. Neurol. Neurosurg. Psychiatry. 58:1995;250-252.
10. Glantz M.J., Hoffman J.M., Coleman R.E., Friedman A.H., Hanson M.W., Burger P.C., Herndon J.E. d, Meisler W.J., Schold S.C. Jr. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann. Neurol. 29:1991;347-355.
11. Bergstrom M., Boethius J., Eriksson L., Greitz T., Ribbe T., Widen L. Head fixation device for reproducible positron alignment in transmission CT and positron emission tomography. J. Comput. Assist. Tomogr. 5:1981;136-141.
12. Pietrzyk U., Herholz K., Fink G., Jacobs A., Mielke R., Slansky I., Wurker M., Heiss W.D. An interactive technique for three-dimensional image registration validation for PET, SPECT, MRI and CT brain studies . J. Nucl. Med. 35:1994;2011-2018.
13. Rehm K., Strother S.C., Anderson J.R., Schaper K.A., Rottenberg D.A. Display of merged multimodality brain images using interleaved pixels with independent color scales. J. Nucl. Med. 35:1994;1815-1821.
14. Hamacher K., Coenen H.H., Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J. Nucl. Med. 27:1986;235-238.
15. Grosu A., Feldmann H., Albrecht C., Kneschaurek P., Wehrmann R., Gross M.W., Zimmermann F.B., Molls M. 3-Dimensionale Bestrahlungsplanung von Hirntumoren: Vorteile der Methode und klinische Ergebnisse. Strahlenther. Onkol. 174:1998;7-13.
16. Coons S., Johnson P. Histopathology of astrocytomas. Grading; patterns of spread; and correlation with modern imaging modalities. Sem. Radiat. Oncol. 1:1991;2-9.
17. Delbeke D., Meyerowitz C., Lapidus R.L., Maciunas R.J., Jennings M.T., Moots P.L., Kessler R.M. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 195:1995;47-52.
18. Karlsson U.L., Leibel S.A., Wallner K., et al. Perez J., Brady J.B. Principles and practice of radiation oncology. 1992;515-563 Lippincott, Philadelphia.
19. Nitta T., Sato K. Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer. 75:1995;2727-2731.
20. Agbi C.B., Bernstein M., Laperriere N., Leung P., Lumley M. Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants. Int. J. Radiat. Oncol. Biol. Phys. 23:1992;321-326.
21. Massey V., Wallner K.E. Patterns of second recurrence of malignant astrocytomas. Int. J. Radiat. Oncol. Biol. Phys. 18:1990;395-398.
22. Marks J.E., Baglan R.J., Prassad S.C., Blank W.F. Cerebral radionecrosis Incidence and risk in relation to dose, time, fractionation and volume . Int. J. Radiat. Oncol. Biol. Phys. 7:1981;243-252.
23. Holzer T., Herholz K., Jeske J., Heiss W.D. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J. Comput. Assist. Tomogr. 17:1993;681-687.
24. Goldman S., Levivier M., Pirotte B., Brucher J.M., Wikler D., Damhaut P., Stanus E., Brotchi J., Hildebrand J. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer. 78:1996;1098-1106.
25. Weber W., Bartenstein P., Groß M.W., Kinzel D., Daschner H., Feldmann H., Reidel G., Ziegler S., Lumenta C., Molls M., Schwaiger M. F-18-Fluorodeoxyglucose PET and I-123-alpha-methyl-tyrosine SPECT in the evaluation of brain tumors. J. Nucl. Med. 38:1997;802-808.